DK167172B1 - Anvendelse af dopaminagonister til fremstilling af laegemidler til behandling af afhaengighed af psykostimulerende stoffer - Google Patents

Anvendelse af dopaminagonister til fremstilling af laegemidler til behandling af afhaengighed af psykostimulerende stoffer Download PDF

Info

Publication number
DK167172B1
DK167172B1 DK207086A DK207086A DK167172B1 DK 167172 B1 DK167172 B1 DK 167172B1 DK 207086 A DK207086 A DK 207086A DK 207086 A DK207086 A DK 207086A DK 167172 B1 DK167172 B1 DK 167172B1
Authority
DK
Denmark
Prior art keywords
dopamine
cocaine
treatment
use according
psychostimulants
Prior art date
Application number
DK207086A
Other languages
Danish (da)
English (en)
Other versions
DK207086A (da
DK207086D0 (da
Inventor
Charles A Dackis
Mark S Gold
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of DK207086D0 publication Critical patent/DK207086D0/da
Publication of DK207086A publication Critical patent/DK207086A/da
Application granted granted Critical
Publication of DK167172B1 publication Critical patent/DK167172B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
DK207086A 1985-05-06 1986-05-05 Anvendelse af dopaminagonister til fremstilling af laegemidler til behandling af afhaengighed af psykostimulerende stoffer DK167172B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73110285A 1985-05-06 1985-05-06
US73110285 1985-05-06
US79118885A 1985-10-25 1985-10-25
US79118885 1985-10-25

Publications (3)

Publication Number Publication Date
DK207086D0 DK207086D0 (da) 1986-05-05
DK207086A DK207086A (da) 1986-11-07
DK167172B1 true DK167172B1 (da) 1993-09-13

Family

ID=27112170

Family Applications (1)

Application Number Title Priority Date Filing Date
DK207086A DK167172B1 (da) 1985-05-06 1986-05-05 Anvendelse af dopaminagonister til fremstilling af laegemidler til behandling af afhaengighed af psykostimulerende stoffer

Country Status (15)

Country Link
EP (1) EP0204954B1 (xx)
JP (1) JPS61293929A (xx)
AT (1) ATE78395T1 (xx)
AU (1) AU591120B2 (xx)
CA (1) CA1277914C (xx)
DE (2) DE3686097T2 (xx)
DK (1) DK167172B1 (xx)
FR (1) FR2587213B1 (xx)
GR (1) GR861128B (xx)
HU (1) HU197512B (xx)
IE (1) IE58884B1 (xx)
IL (1) IL78689A (xx)
IT (1) IT1203782B (xx)
NZ (1) NZ216050A (xx)
PT (1) PT82515B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3814521A1 (de) * 1987-05-07 1988-11-17 Sandoz Ag Neue anwendung von dopaminrezeptor-agonisten
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
AU629688B2 (en) * 1989-08-03 1992-10-08 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Slowly dissociating (tight binding) dopamine, serotonin or norepinephrine reuptake inhibitors as cocaine, amphetamine and phencyclidine antagonists
US6623752B1 (en) 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid
DE19626621A1 (de) * 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
CA2304592A1 (en) 1997-09-24 1999-04-01 The General Hospital Corporation Inhibition of psychostimulant-induced and nicotine-induced craving
WO2019091870A1 (en) * 2017-11-08 2019-05-16 4P-Pharma Stimulant abuse-deterrent compositions
EP4316482A1 (en) * 2022-08-01 2024-02-07 4P-Pharma Levodopa for preventing addiction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995058A (en) * 1973-12-12 1976-11-30 Miles Laboratories, Inc. Treatment of ethanol withdrawal symptoms with levodopa

Also Published As

Publication number Publication date
IT8647977A0 (it) 1986-05-05
DE3686097T2 (de) 1993-01-07
HUT40915A (en) 1987-03-30
NZ216050A (en) 1989-08-29
PT82515B (pt) 1988-10-14
IL78689A0 (en) 1986-08-31
DE3615190A1 (de) 1987-05-21
IE861189L (en) 1986-11-06
EP0204954A3 (en) 1989-11-08
AU5710986A (en) 1986-11-13
FR2587213A1 (fr) 1987-03-20
ATE78395T1 (de) 1992-08-15
EP0204954B1 (en) 1992-07-22
DK207086A (da) 1986-11-07
JPH0569093B2 (xx) 1993-09-30
GR861128B (en) 1986-08-26
IE58884B1 (en) 1993-12-01
IL78689A (en) 1990-09-17
JPS61293929A (ja) 1986-12-24
AU591120B2 (en) 1989-11-30
IT1203782B (it) 1989-02-23
PT82515A (en) 1986-06-01
FR2587213B1 (fr) 1990-06-08
EP0204954A2 (en) 1986-12-17
HU197512B (en) 1989-04-28
DE3686097D1 (de) 1992-08-27
CA1277914C (en) 1990-12-18
DK207086D0 (da) 1986-05-05

Similar Documents

Publication Publication Date Title
Hanotin et al. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study
US4935429A (en) Method of treating psychostimulant addiction
Coccaro et al. Second generation antidepressants: a comparative review
AU2004216452B2 (en) Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug
Parkes et al. Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.
AU703242B2 (en) Film coated tablet of paracetamol and domperidone
US20020048612A1 (en) GABA substrate and the use thereof for treating cognitive and emotional disorders
JPS59193821A (ja) 抗不安薬としてのフルオキセチンの使用法
DK167172B1 (da) Anvendelse af dopaminagonister til fremstilling af laegemidler til behandling af afhaengighed af psykostimulerende stoffer
Siegfried et al. Cognitive and psychomotor effects of different antidepressants in the treatment of old age depression
EP1173167A1 (en) Treatment of female arousal disorder
WO2000010554A2 (en) Methods and compositions employing optically pure s(+) vigabatrin
NO309965B1 (no) Oralt farmasøytisk antihostepreparat
IL43820A (en) Pharmacological preparations for the treatment of deformed disabled, containing symptomatic aminophytic bronchodilators
Challoner et al. Pentazocine (Talwin®) intoxication: Report of 57 cases
Bever et al. Dexfenfluramine hydrochloride: an anorexigenic agent
CA2471338C (en) Use of deoxypeganine for treating clinical depression
Carpenter et al. Drug treatment of obesity in type 2 diabetes mellitus
KR100692235B1 (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
CN110279691B (zh) 一种外科术后护理镇痛药物及其用途
Brogden et al. Terbutaline: a preliminary report of its pharmacological properties and therapeutic efficacy in asthma
Finnegan et al. An Evaluation of Neonatal Abstinence Treatment Modalities¹
MXPA01013403A (es) Nueva asociacion farmaceutica con accion analgesica que contiene paracetamol y buspirona.
Raskind Nutrition and cognitive function in the elderly
US6281248B1 (en) Composition for treating asthma

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed